Patrick Ogle Takes 15.9% Stake in cbdMD, Gains Board Nomination Right

Patrick Ogle, via Akretive Holdings, acquired 2.23 million shares of cbdMD (15.9% stake) on October 30, 2026. The asset purchase agreement grants Akretive the right to nominate a director for cbdMD's committee, but not a guaranteed board seat. Akretive also holds a senior secured promissory note.

Original reporting
Published Nov 5, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Patrick Ogle Takes 15.9% Stake in cbdMD, Gains Board Nomination Right — source image
Decision brief

The 30-second read

$YCBDBullishMed
01

Why it matters

The 13D filing introduces a new major shareholder with board nomination rights, which may affect corporate governance and future strategic direction.

02

Market read

The filing is a primary disclosure for a micro‑cap, likely prompting short‑term price movement and increased analyst coverage.

03

What to watch

Potential future dilution if the investor seeks additional capital or a merger.

Relevance 6/10Novelty 7/10Timing: immediate, after filing release

Background

cbdMD, Inc. is a publicly traded cannabis‑derived pharmaceutical company listed on the OTC market under the ticker YCBD.

Company-level read

Ticker impact

$YCBDBullishHigh confidence
Context

Patrick Ogle, via Akretive Holdings, acquired a 15.9% stake in cbdMD, Inc. by purchasing 2,229,805 shares under a newly filed Schedule 13D.

Expected impact

likely upward pressure as the market prices in the large stake and potential board influence

Evidence & confidence

A 13D filing revealing a near‑20% stake is material for a micro‑cap; such ownership changes often lead to short‑term buying interest.

Market effects

May draw attention to the cannabis sector and could influence peer valuations.

Primarily U.S. OTC market; limited broader regional effect.

Low global relevance beyond niche cannabis investors.

Counterpoint

The stake could be a strategic move to push for changes that may unsettle current management.

Key entities

  • Patrick Ogle

    Managing member of Akretive LLC, leading the acquisition of a 15.9% stake in cbdMD.

  • Akretive Holdings, LLC

    Entity used by Ogle to purchase shares and a senior secured promissory note.

Related articles

$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

$YCBDMed

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

cbdMD, Inc. (NYSE American: YCBD) reported Q3 FY2026 results ended June 30, 2026. Revenue rose 20% year over year to $5.6 million, driven by 61% higher wholesale net sales and a full quarter contribution from Bluebird Botanicals. Oasis distribution expanded. Loss from operations was about $1.13 million. The company cited federal hemp legislation timing and expected monthly cost savings up to $150,000.

$SNDKLow

Leopold Aschenbrenner’s AI Fund Cut Its Reported Holdings 92% in One Quarter

Leopold Aschenbrenner's AI fund, Situational Awareness, reduced its reported holdings by 92% to $1.58 billion in Q3, according to 13F filings. The fund sold stakes in SanDisk, Micron, Bloom Energy, Nebius, and CoreWeave, shifting into options. New top holding is SharonAI at $441 million. Micron and SanDisk reported revenue growth, while Bloom raised guidance. CoreWeave and Nebius faced financial challenges.